A detailed history of Wells Fargo & Company transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 24,315 shares of TNYA stock, worth $40,362. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,315
Previous 22,421 8.45%
Holding current value
$40,362
Previous $69,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.93 - $3.99 $3,655 - $7,557
1,894 Added 8.45%
24,315 $46,000
Q2 2024

Aug 13, 2024

BUY
$2.72 - $4.99 $16,281 - $29,870
5,986 Added 36.42%
22,421 $69,000
Q1 2024

May 10, 2024

BUY
$2.88 - $6.8 $6,189 - $14,613
2,149 Added 15.04%
16,435 $85,000
Q4 2023

Feb 09, 2024

BUY
$1.73 - $3.39 $5,169 - $10,129
2,988 Added 26.45%
14,286 $46,000
Q3 2023

Nov 13, 2023

SELL
$2.55 - $5.65 $15,468 - $34,272
-6,066 Reduced 34.93%
11,298 $28,000
Q2 2023

Aug 15, 2023

BUY
$2.64 - $7.64 $25,689 - $74,344
9,731 Added 127.49%
17,364 $101,000
Q1 2023

May 12, 2023

BUY
$1.92 - $3.59 $14,655 - $27,402
7,633 New
7,633 $21,000
Q3 2022

Nov 14, 2022

SELL
$2.9 - $5.88 $638 - $1,293
-220 Reduced 86.61%
34 $0
Q2 2022

Aug 12, 2022

SELL
$5.01 - $14.12 $87,309 - $246,069
-17,427 Reduced 98.56%
254 $1,000
Q1 2022

May 16, 2022

SELL
$9.41 - $19.3 $9,325 - $19,126
-991 Reduced 5.31%
17,681 $208,000
Q4 2021

Feb 14, 2022

BUY
$18.41 - $29.58 $342,333 - $550,040
18,595 Added 24149.35%
18,672 $354,000
Q3 2021

Nov 15, 2021

BUY
$15.35 - $26.66 $1,181 - $2,052
77 New
77 $2,000

Others Institutions Holding TNYA

About Tenaya Therapeutics, Inc.


  • Ticker TNYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,364,700
  • Market Cap $68.7M
  • Description
  • Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...
More about TNYA
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.